BodyPharm Semaglutide 6mg Multi-Dose Injection Pen

Format: Pre-filled multi-dose subcutaneous injection pen

Concentration: 6mg semaglutide per pen (dial settings: 0.25mg / 0.5mg / 0.75mg / 1mg increments)

Excipients: Disodium phosphate dihydrate, propylene glycol, phenol, sterile water

Use restriction: Single patient/single research subject use only

Packaging: Boxed pen with tamper-evident seal

Manufacturer: BodyPharm

Research Protocol Overview

Published clinical trials have generally evaluated semaglutide using:

• 
  Once-weekly administration
  
• 
  A gradual dose-escalation strategy to improve gastrointestinal tolerability
  
• 
  Predetermined maintenance doses after the escalation period
  
• 
  Regular monitoring of metabolic outcomes, safety, and adverse events throughout the study period
  

The escalation strategy used in clinical studies was intended to reduce gastrointestinal side effects while assessing efficacy and tolerability.

Research Monitoring

Researchers typically monitor:

• 
  Body weight
  
• 
  HbA1c
  
• 
  Fasting blood glucose
  
• 
  Blood pressure
  
• 
  Gastrointestinal tolerability
  
• 
  Laboratory parameters
  
• 
  Adverse events
  
• 
  Overall treatment response
  

Storage

• 
  Store according to the manufacturer's recommendations.
  
• 
  Protect from excessive heat, freezing, and direct sunlight.
  
• 
  Do not use if the pen appears damaged or if the solution is discolored or contains particles.
  

Research Status

Semaglutide has been extensively studied in large clinical trial programs for obesity, type 2 diabetes, cardiovascular outcomes, and additional metabolic conditions. Ongoing research continues to evaluate its long-term efficacy and safety across multiple therapeutic areas.

Key References

• 
  STEP Clinical Trial Program
  
• 
  SUSTAIN Clinical Trial Program
  
• 
  SELECT Cardiovascular Outcomes Trial
  
• 
  FDA-approved prescribing information for semaglutide products
  

FAQ's

Q: Is this the same as prescription semaglutide (Ozempic/Wegovy)?
A: No. While semaglutide as a molecule is FDA-approved under those brand names for clinical use, this product is a separately manufactured research-grade compound sold strictly for laboratory research — it is not sourced from, affiliated with, or equivalent to the approved pharmaceutical product.

Q: Who can purchase this product?
A: This listing is intended for qualified researchers, laboratories, and institutions conducting legitimate scientific research — not for personal or clinical use.

Q: How should the pen be stored?
A: Store according to cold-chain guidelines (refrigerated, protected from light). Refer to the product insert for exact storage specifications, as peptide compounds are typically temperature-sensitive.

Q: What's included in the box?
A: One 6mg multi-dose semaglutide pen with excipient information printed on the packaging.

Research Overview

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk and approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It underpins the STEP clinical trial program, one of the largest research efforts into GLP-1-based weight management.

Key published findings:

• The pivotal STEP 1 trial found 1,961 participants were enrolled, with those receiving once-weekly semaglutide 2.4mg achieving an average weight loss of 14.85% at week 68, compared to 2.41% with placebo. clinicaltrials
• A pooled analysis of the STEP program found semaglutide combined with lifestyle intervention produced significantly greater weight loss than placebo over 68 weeks, with 86.4%, 69.1%, and 50.5% of participants achieving weight loss of at least 5%, 10%, and 15% respectively, alongside improvements in blood pressure, cholesterol, glycemic markers, and inflammatory markers. nihnih
• The STEP 5 trial examined longer-term outcomes and found sustained weight loss was maintained over a 104-week period in 304 participants randomized to semaglutide 2.4mg or placebo. NatureNature
• More recent Phase 3b data from the STEP UP trial found an investigational higher dose of 7.2mg produced a mean weight loss of 21% in adults with obesity without diabetes, with a tolerable safety profile, and over 90% of participants on the 7.2mg dose achieved at least 5% weight loss. Applied Clinical Trials OnlineApplied Clinical Trials Online
• Semaglutide has also been studied beyond weight management — the STEP-HFpEF trial found semaglutide improved symptoms, physical limitations, and exercise function while reducing body weight in patients with obesity-related heart failure with preserved ejection fraction. nih